[Skip to Content]
[Skip to Content Landing]
August 30, 1971

Medical News

JAMA. 1971;217(9):1173-1182. doi:10.1001/jama.1971.03190090005003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Immunologists hear about results of bone-marrow transplants  Twelve young patients have thus far survived dual, inborn immunodeficiencies with the aid of bone-marrow transplantation, Robert A. Good, MD, told the First International Congress on Immunology in Washington, DC.A key to success is the use of marrow from siblings matched at the major HL-A histocompatibility locus. Earlier, animal experiments had shown that fatal graft-versus-host (GVH) reactions did not often occur if donor and recipient were mismatched at minor histocompatibility determinants."We conclude from these findings that the first toddling steps have already been taken in an era which will utilize cellular engineering as an integral component of its therapeutic armamentarium," said the immunologist from the University of Minnesota.He added that the technique may be potentially useful in treating other diseases, as well as immunodeficiency.The marrow transplants have been performed at several major medical centers. The first two were